The study focuses on a blood biomarker that measures astrocyte reactivity to predict the development of Alzheimer's disease in cognitively unimpaired older adults with amyloid-beta. The research suggests that a combination of amyloid-beta burden and abnormal astrocyte activation leads to progression to AD. The study emphasizes the importance of testing for brain amyloid and blood biomarkers of astrocyte reactivity for optimal screening to identify individuals at risk for Alzheimer's disease. The findings suggest that astrocyte reactivity is an early event preceding tau pathology, indicating a potential link to neurodegeneration and cognitive decline.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Pauline Ande... at www.medscape.com 06-06-2023
https://www.medscape.com/viewarticle/992830Deeper Inquiries